| Study [ref#] | No. of patients | Markers | Disorder |
| Milosevic et al. 2012 [48] | 203 | TP53, RUNX1, CBL, IDH1/2, NRAS, NPM1, and FLT3 | MDS, AML, and MPN | Shih et al. 2012 [49] | — | TET2, IDH1/2, ASXL1, EZH2, and DNMT3A | MDS, AML, and MPN | Patel et al. 2012 [25] | 398 | TET2, ASXL1, DNMT3A, CEBPA, PHF6, WT1, TP53, EZH2, RUNX1, PTEN FLT3, NPM1, HRAS, KRAS, NRAS, KIT, IDH1, and IDH2 | AML | Brecqueville et al. 2012 [41] | 276 | ASXL1, CBL, DNMT3A, IDH1/2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 | MPN | Yoshida et al. 2011 [50] | 29 | U2AF35, ZRSR2, SRSF2, and SF3B1 | MDS | Zhang et al. 2012 [51] | 53 | SRSF2 | MPN and AML | Langemeijer et al. 2011 [44] | 151 | TET2 | AML | Schnittger et al. 2012 [52] | 636 | CBL, JAK2, and TET2 | MPN | Thiede 2012 [53] | — | FLT3, NPM1, TET2, IDH1/2, and DNMT3A | AML | Bejar et al. 2011 [42] | 439 | ETV6, GNAS, RUNX1, TP53, EZH2, and NRAS | MDS | Cimmino et al. 2011 [54] | — | TET family | MDS, AML, and MPN |
|
|